Compare CAKE & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | ORKA |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.6B |
| IPO Year | 1996 | 1997 |
| Metric | CAKE | ORKA |
|---|---|---|
| Price | $115.97 | $74.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | $99.20 | ★ $155.00 |
| AVG Volume (30 Days) | ★ 1.2M | 927.3K |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $3,751,806,000.00 | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | $47.35 | ★ N/A |
| Revenue Growth | ★ 4.75 | N/A |
| 52 Week Low | $43.07 | $25.11 |
| 52 Week High | $118.63 | $115.52 |
| Indicator | CAKE | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 35.78 |
| Support Level | $102.42 | $54.31 |
| Resistance Level | $117.12 | $97.45 |
| Average True Range (ATR) | 3.21 | 3.55 |
| MACD | 0.91 | -0.50 |
| Stochastic Oscillator | 79.94 | 32.50 |
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.